Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Gains from Investment Securities (2016 - 2023)

VYNE Therapeutics (VYNE) has disclosed Gains from Investment Securities for 7 consecutive years, with $58000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gains from Investment Securities changed N/A year-over-year to $58000.0, compared with a TTM value of $58000.0 through Sep 2024, down 61.07%, and an annual FY2023 reading of $207000.0, changed N/A over the prior year.
  • Gains from Investment Securities was $58000.0 for Q4 2023 at VYNE Therapeutics, down from $149000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.7 million in Q2 2020 and bottomed at -$4.9 million in Q3 2020.
  • Average Gains from Investment Securities over 4 years is $56640.2, with a median of $75000.0 recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 4980.42% in 2020, while the deepest fall reached 501.47% in 2020.
  • Year by year, Gains from Investment Securities stood at -$1.2 million in 2019, then rose by 15.68% to -$979000.0 in 2020, then surged by 260.88% to $1.6 million in 2021, then tumbled by 96.32% to $58000.0 in 2023.
  • Business Quant data shows Gains from Investment Securities for VYNE at $58000.0 in Q4 2023, $149000.0 in Q1 2023, and $1.6 million in Q4 2021.